No Data
No Data
Investors Still Aren't Entirely Convinced By Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Revenues Despite 27% Price Jump
Yifan Pharmaceutical Co., Ltd. (SZSE:002019) shareholders would be excited to see that the share price has had a great month, posting a 27% gain and recovering from prior weakness. The bad news is
Yifan Pharmaceutical Unit Gets Authorization to Sell Circulation Supplement in Singapore
Yifan Pharmaceutical's (SHE:002019) unit, SciGen, received approval from Singapore's Health Sciences Authority to register and market its Ginkgo leaf pills in the city-state, according to a filing wit
Yifan Pharmaceutical (002019.SZ): Diet drug products are currently in the preclinical research stage
Gelonghui, May 8, 丨 Yifan Pharmaceutical (002019.SZ) held a performance briefing on May 7, 2024 to discuss “Does the company have diet medicine products?” The company replied that the company's diet drug products are currently in the pre-clinical research stage.
Yifan Pharmaceutical (002019.SZ): Heroda is expected to achieve annual revenue of 500 to 1 billion yuan
Gelonghui, May 8, 丨 Yifan Pharmaceutical (002019.SZ) held a performance briefing on May 7, 2024 to discuss “How much revenue is Heroda expected to contribute each year?” The company replied that according to the current sales situation, it is expected to achieve annual revenue of 500 to 1 billion yuan.
Yifan Pharmaceutical (002019.SZ): The Hangzhou production base is expected to have some production capacity between the end of 2024 and the first quarter of 2025
Gelonghui, May 8, 丨 Yifan Pharmaceutical (002019.SZ) held a performance briefing on May 7, 2024, to discuss “What stage has the Hangzhou Synthetic Biology Industrial Park reached? Can the first phase be tested?” The company replied that the Hangzhou production base is under construction according to the plan and is expected to have some production capacity between the end of 2024 and the first quarter of 2025.
Yifan Unit's Allergy Drug Passes China Regulatory Test, Stock Price Jumps
Yifan Pharmaceutical (SHE:002019) unit Sichuan Defeng Pharmaceutical's emestine fumarate sustained-release capsules passed the consistency evaluation by China's National Medical Products Administratio
No Data